



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/475, 14/52, 16/24, C12N 5/10, 15/12, 15/19, 15/63, 15/64, A61K 38/19, 48/00, 39/395	A1	(11) International Publication Number: WO 98/56818 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/US98/11908 (22) International Filing Date: 10 June 1998 (10.06.98) (30) Priority Data: 08/872,704 11 June 1997 (11.06.97) US 09/094,287 9 June 1998 (09.06.98) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). (74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMAN L105 PROTEINS AND POLYNUCLEOTIDES ENCODING SAME		
(57) Abstract A chemokine, human L105, is disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HUMAN L105 PROTEINS AND POLYNUCLEOTIDES ENCODING SAME

5 This application is a continuation-in-part of application Ser. No. 60/XXX,XXX (converted to a provisional application from non-provisional application Ser. No. 08/872,704), filed June 11, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention provides chemokines called human L105 proteins and polynucleotides encoding them.

BACKGROUND OF THE INVENTION

Chemokines are a subclass of cytokines which cause the directed migration or
15 chemotaxis of particular cell populations either to or away from higher concentrations of the chemokine. Many chemokines have been identified which cause migration of major blood cell populations. These factors may be useful for directing the migration of cell populations to areas of desired action or away from areas of unwanted action. It would, therefore, be desirable to identify new chemokines and polynucleotides encoding them.

20 Applicants' U.S. Patent No. 5,707,829 and published international patent application WO97/07198 disclose a novel murine chemokine identified as "L105." Murine L105 has been demonstrated to have chemokinetic/chemoattractant activity for several cell types, including thymocytes, kidney mesangial cells and lymphocytes localized in lymph nodes. Because of these beneficial activities, it would be desirable to identify human homologues of murine
25 L105.

SUMMARY

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 80 to nucleotide 481;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 149 to nucleotide 481;
- (c) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1 encoding a protein having chemokine activity;
- 10 (d) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity;
- 15 (g) a polynucleotide which is an allelic variant of SEQ ID NO:1;
- (h) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 85 to nucleotide 519;
- (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 124 to nucleotide 519;
- 20 (j) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3 encoding a protein having chemokine activity;
- (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- 25 (l) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145;

(m) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having chemokine activity;

(n) a polynucleotide which is an allelic variant of SEQ ID NO:3; and

(o) a polynucleotide capable of hybridizing to any one of the polynucleotides specified in (a), (b), (d), (e), (h), (i), (k) or (l) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 80 to nucleotide 481; the nucleotide sequence of SEQ ID NO:1 from nucleotide 119 to nucleotide 481; the nucleotide sequence of the full-length protein coding sequence of clone huL105_3 deposited under accession number ATCC 98429; or the nucleotide sequence of a mature protein coding sequence of clone huL105_3 deposited under accession number ATCC 98429. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone huL105_3 deposited under accession number ATCC 98429. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity, the fragment comprising the amino acid sequence from amino acid 62 to amino acid 71 of SEQ ID NO:2.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 85 to nucleotide 519; the nucleotide sequence of SEQ ID NO:3 from nucleotide 124 to nucleotide 519; the nucleotide sequence of the full-length protein coding sequence of clone huL105_7 deposited under accession number ATCC 98431; or the nucleotide sequence of a mature protein coding sequence of clone huL105_7 deposited under accession number ATCC 98431. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone huL105_7 deposited

under accession number ATCC 98431. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 124 to amino acid 134. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having chemokine activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having chemokine activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:4.

10 In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Other embodiments provide an isolated gene corresponding to the cDNA sequence of SEQ ID NO:1, and an isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.

20 Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Compositions comprising a protein having chemokine activity are also disclosed. In preferred embodiments the protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;

- (b) the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134;
- (c) fragments of the amino acid sequence of SEQ ID NO:2 having chemokine activity;
- 5 (d) the amino acid sequence of SEQ ID NO:4;
- (e) the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145; and
- (f) fragments of the amino acid sequence of SEQ ID NO:4 having chemokine activity;
- 10 the protein being substantially free from other mammalian proteins.

Preferably such protein comprises the amino acid sequence of SEQ ID NO:2, or the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity, the fragment preferably

15 comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity, the fragment comprising the amino acid sequence from amino acid 62 to amino acid 71 of SEQ ID NO:2.

Preferably such protein comprises the amino acid sequence of SEQ ID NO:4, the

20 amino acid sequence of SEQ ID NO:4 from amino acid 124 to amino acid 134, or the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having chemokine activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of

25 SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID

NO:4 having chemokine activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:4.

Such compositions may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also
5 provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

10

DETAILED DESCRIPTION

The sequence for the human L105 was found in the Genbank EST database by searching using the murine L105 sequence (polynucleotide, SEQ ID NO:5; protein, SEQ ID NO:6). The search revealed two possible related human ESTs, AA027314 (SEQ ID NO:7)
15 and W17274 (SEQ ID NO:8), which partially overlapped.

A probe of sequence CXTCCATCACTGCCTTGGGTCCTGGGGAT (X=biotin) (SEQ ID NO:9) was designed to isolate a full-length human L105 clone. The probe was used to screen a human adult heart cDNA library. The screening revealed to full-length clones, which were identified as "huL105_3" and "huL105_7".

20 The polynucleotide and amino acid sequences of huL105_3 is reported as SEQ ID NO:1 and SEQ ID NO:2, respectively. The coding sequence of huL105_3 includes nucleotides 80-481, which encode a 134 amino acid full-length protein. The mature protein begins at amino acid 14 (SEQ ID NO:2).

The polynucleotide and amino acid sequences of huL105_7 is reported as SEQ ID
25 NO:3 and SEQ ID NO:4, respectively. The coding sequence of huL105_7 includes

nucleotides 85-519, which encode a 145 amino acid full-length protein. The mature protein begins at amino acid 14 (SEQ ID NO:4).

Comparison of huL105_3 and huL105_7 reveal that huL105_7 contains an insertion relative to huL105_3. The inserted region is found at nucleotides 454-486 of SEQ ID NO:3.

5 This region encodes additional amino acids 124-134 in SEQ ID NO:4.

huL105_3 and huL105_7 cDNAs were deposited on May 9, 1997 under the Budapest Treaty with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) and were assigned accession numbers ATCC 98429 and ATCC 98431, respectively. All restrictions on the availability to the public of the deposited material
10 will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Comparison of the human L105 sequences (SEQ ID NO:2 and SEQ ID NO:4) to the murine L105 sequence (SEQ ID NO:6) confirms that these proteins are human homologues
15 of the murine chemokine. As a result, the human L105 proteins share the chemokinetic activities of murine L105.

Fragments of the proteins of the present invention which are capable of exhibiting
20 biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many
25 purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an

immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

5 The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of
10 the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.

 The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived
15 and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such
20 methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

25 Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired

change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* **15**(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* **62**(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* **58**: 1-39; all of which are
5 incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal
10 or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete
15 gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* **14**(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* **90**(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* **91**(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection
20 strategies (Mansour *et al.*, 1988, *Nature* **336**: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the
25 development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most

preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*,
5 *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* **22**: 323-351; O'Brien *et al.*, 1993, *Nature*
10 *Genetics* **3**:103-112; Johansson *et al.*, 1995, *Genomics* **25**: 682-690; Lyons *et al.*, 1997, *Nature Genetics* **15**: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* **13**(10): 393-399; Carver and Stubbs, 1997, *Genome Research* **7**:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or
15 proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by
20 comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those
25 of the polynucleotides disclosed herein.

The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least
5 as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

	Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [‡]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
5	A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	DNA:DNA	<50	T _B *; 1xSSC	T _B *; 1xSSC
	C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	DNA:RNA	<50	T _D *; 1xSSC	T _D *; 1xSSC
	E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	RNA:RNA	<50	T _F *; 1xSSC	T _F *; 1xSSC
10	G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	DNA:DNA	<50	T _H *; 4xSSC	T _H *; 4xSSC
	I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	DNA:RNA	<50	T _J *; 4xSSC	T _J *; 4xSSC
	K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	RNA:RNA	<50	T _L *; 2xSSC	T _L *; 2xSSC
15	M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	DNA:DNA	<50	T _N *; 6xSSC	T _N *; 6xSSC
	O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	DNA:RNA	<50	T _P *; 6xSSC	T _P *; 6xSSC
	Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	RNA:RNA	<50	T _R *; 4xSSC	T _R *; 4xSSC

[‡]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†]: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

*T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived

from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include
5 *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation
10 or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell
15 expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

20 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which
25 will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps

involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of
5 maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from
10 Kodak (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a
15 substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are
20 characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with
25 proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural,

purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally
5 provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the
10 conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected
15 to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

A protein of the present invention may have chemotactic or chemokinetic activity
20 (e.g., act as a chemokine) for mammalian cells, including, for example, lymphocytes (such as, for example, thymocytes, monocytes, neutrophils and T-cells), mast cells, eosinophils and/or endothelial cells. Murine L105 protein has been shown to be chemotactic for thymocytes, kidney mesangial cells and lymphocytes localized in lymph nodes. Human L105 protein shares these activities, as well as possessing other chemotactic and chemokinetic activities.

25 Chemotactic and chemokinetic proteins can be used to mobilized or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide

particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

5 The chemokinetic proteins of the present invention can also be used to block chemotaxis (e.g., by flooding the blood with the proteins and inducing "chemotactic paralysis" (i.e., there is no gradient for cells to move along, so no movement occurs)), such as to block inflammation.

 A protein or peptide has chemotactic activity for a particular cell population if it can
10 stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

15 A protein has "chemokine activity" if it either (1) displays chemoattractant or chemotactic activity in a chemoattraction or chemotaxis assay (preferably an assay in which the corresponding species mature protein is active), or (2) displays biological activity in a factor-dependent cell proliferation assay (preferably an assay in which the corresponding species mature protein is active), or (3) displays activity in the induction of lymphokine
20 production or effector function in an immune cell functional assay. Examples of effector function include, without limitation, tumoricidal activity, granule release, adhesion molecule expression, and the like.

 Activity may be monitored using assays known in the art. Chemoattractant or chemotactic activity can also be measured *in vivo* by injecting protein at a particular site and
25 performing a histological examination of the cell types that migrate to the site of injection.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic

effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic
5 or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

10 The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by
15 MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to
20 bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as
25 micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides,

sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

5 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered
10 alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

 In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a
15 condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s),
20 lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

25 Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety

of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to
5 treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention
10 should contain about 0.01 µg to about 100 mg (preferably about 0.1 µg to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated
15 that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal
20 and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85,
25 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the

immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the
5 protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other
10 known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15

Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Racie, Lisa
Jacobs, Kenneth
- (ii) TITLE OF INVENTION: Human L105 Proteins and Polynucleotide
Encoding Same
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Genetics Institute, Inc.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: Massachusetts
 - (E) COUNTRY: USA
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Brown, Scott A.
 - (B) REGISTRATION NUMBER: 32,724
 - (C) REFERENCE/DOCKET NUMBER: GI5299
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 617-498-8224
 - (B) TELEFAX: 617-876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 908 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 80..481

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
- (B) LOCATION: 149..481

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGGCC AAAGAGGCCT ACTTGCAGCT GCCCACCTCA CCCTCAGCTC TGGCCTCTGT	60
CTCACCTCTCT ACCACAGACA TGGCTCAGTC ACTGGCTCTG AGCCTCCTTA TCCTGGTTCT	120
GGCCTTTGGC ATCCCCAGGA CCCAAGGCAG TGATGGAGGG GCTCAGGACT GTTGCCTCAA	180
GTACAGCCAA AGGAAGATTC CCGCCAAGGT TGTCCGCAGC TACCGGAAGC AGGAACCAAG	240
CTTAGGCTGC TCCATCCCAG CTATCCTGTT CTTGCCCCGC AAGCGCTCTC AGGCAGAGCT	300
ATGTGCAGAC CCAAAGGAGC TCTGGGTGCA GCAGCTGATG CAGCATCTGG ACAAGACACC	360
ATCCCCACAG AAACCAGCCC AGGGCTGCAG GAAGGACAGG GGGGCCTCCA AGACTGGCAA	420
GAAAGGAAAG GGCTCCAAAG GCTGCAAGAG GACTGAGCGG TCACAGACCC CTAAAGGGCC	480
ATAGCCCAGT GAGCAGCCTG GAGCCCTGGA GACCCACCA GCCTCACCAG CGCTTGAAGC	540
CTGAACCCAA GATGCAAGAA GGAGGCTATG CTCAGGGGCC CTGGAGCAGC CACCCCATGC	600
TGGCCTTGCC AACTCTTTC TCCTGCTTTA ACCACCCCAT CTGCATTCCC AGCTCTACCC	660
TGCATGGCTG AGCTGCCCAC AGCAGGCCAG GTCCAGAGAG ACCGAGGAGG GAGAGTCTCC	720
CAGGGAGCAT GAGAGGAGGC AGCAGGACTG TCCCCTTGAA GGAGAATCAT CAGGACCCTG	780
GACCTGATAC GGCTCCCCAG TACACCCAC CTCTTCCTTG TAAATATGAT TTATACCTAA	840
CTGAATAAAA AGCTGTTCTG TCTTCCCACC CAAAAAAAAA AAAAAATTGA ATTCTAGACC	900
TGCGGCCCG	908

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 134 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

[illegible]

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 932 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 85..519

(ix) FEATURE:

- ```
(A) NAME/KEY: mat_peptide
(B) LOCATION: 154..519
```

GAATTCGGCC AAAGAGGCCT ACCCAACTTG CAGCTGCCCA CCTCACCCTC AGCTCTGGCC 60

TCTTACTCAC CCTTACCAC AGACATGGCT CAGTCACTGG CTCTGAGCCT CCTTATCCTG 120

```

GTTCTGGCCT TTGGCATCCC CAGGACCCAA GGCAGTGATG GAGGGGCTCA GGACTGTTGC 180
CTCAAGTACA GCCAAAGGAA GATTCCCGCC AAGGTTGTCC GCAGCTACCG GAAGCAGGAA 240
CCAAGCTTAG GCTGCTCCAT CCCAGCTATC CTGTTCTTGC CCCGCAAGCG CTCTCAGGCA 300
GAGCTATGTG CAGACCCAAA GGAGCTCTGG GTGCAGCAGC TGATGCAGCA TCTGGACAAG 360
ACACCATCCC CACAGAAACC AGCCCAGGGC TGCAGGAAGG ACAGGGGGGC CTCCAAGACT 420
GGCAAGAAAG GAAAGGGCTC CAAAGGCTGC AAGAGTCAGC CCCTCACACC CCTCTTCTGC 480
CCTCACAGGA CTGAGCGGTC ACAGACCCCT AAAGGGCCAT AGCCCAGTGA GCAGCCTGGA 540
GCCCTGGAGA CCCCACCAGC CTCACCAGCG CTTGAAGCCT GAACCCAAGA TGCAAGAAGG 600
AGGCTATGCT CAGGGGCCCT GGAGCAGCCA CCCCATGCTG GCCTTGCCAC ACTCTTTCTC 660
CTGCTTTAAC CACCCCATCT GCATTCCAG CTCTACCCTG CATGGCTGAG CTGCCCACAG 720
CAGGCCAGGT CCAGAGAGAC CGAGGAGGGA GAGTCTCCCA GGGAGCATGA GAGGAGGCAG 780
CAGGACTGTC CCCTTGAAGG AGAATCATCA GGACCCTGGA CCTGATACGG CTCCCCAGTA 840
CACCCCACCT CTTCTTGTA AATATGATTT ATACCTAACT GAATAAAAAG CTGTTCTGTC 900
TTCCACCCAA AAAAAAAAAA AAAAGCGGCC GC 932

```

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ala Gln Ser Leu Ala Leu Ser Leu Leu Ile Leu Val Leu Ala Phe
1 5 10 15
Gly Ile Pro Arg Thr Gln Gly Ser Asp Gly Gly Ala Gln Asp Cys Cys
20 25 30
Leu Lys Tyr Ser Gln Arg Lys Ile Pro Ala Lys Val Val Arg Ser Tyr
35 40 45
Arg Lys Gln Glu Pro Ser Leu Gly Cys Ser Ile Pro Ala Ile Leu Phe
50 55 60

```

Leu Pro Arg Lys Arg Ser Gln Ala Glu Leu Cys Ala Asp Pro Lys Glu  
 65 70 75 80  
 Leu Trp Val Gln Gln Leu Met Gln His Leu Asp Lys Thr Pro Ser Pro  
 85 90 95  
 Gln Lys Pro Ala Gln Gly Cys Arg Lys Asp Arg Gly Ala Ser Lys Thr  
 100 105 110  
 Gly Lys Lys Gly Lys Gly Ser Lys Gly Cys Lys Ser Gln Pro Leu Thr  
 115 120 125  
 Pro Leu Phe Cys Pro His Arg Thr Glu Arg Ser Gln Thr Pro Lys Gly  
 130 135 140  
 Pro  
 145

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 588 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (iii) HYPOTHETICAL: NO

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 76..474

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGGCCAAAGA GGCCTAAACT TCGGGCTGTC CATCTCACCT ACAGCTCTGG TCTCATCCTC 60  
 AACTCAACCA CAATC ATG GCT CAG ATG ATG ACT CTG AGC CTC CTT AGC CTG 111  
 Met Ala Gln Met Met Thr Leu Ser Leu Leu Ser Leu  
 1 5 10  
 GTC CTG GCT CTC TGC ATC CCC TGG ACC CAA GGC AGT GAT GGA GGG GGT 159  
 Val Leu Ala Leu Cys Ile Pro Trp Thr Gln Gly Ser Asp Gly Gly Gly  
 15 20 25  
 CAG GAC TGC TGC CTT AAG TAC AGC CAG AAG AAA ATT CCC TAC AGT ATT 207  
 Gln Asp Cys Cys Leu Lys Tyr Ser Gln Lys Lys Ile Pro Tyr Ser Ile  
 30 35 40  
 GTC CGA GGC TAT AGG AAG CAA GAA CCA AGT TTA GGC TGT CCC ATC CCG 255  
 Val Arg Gly Tyr Arg Lys Gln Glu Pro Ser Leu Gly Cys Pro Ile Pro  
 45 50 55 60

GCA ATC CTG TTC TCA CCC CGG AAG CAC TCT AAG CCT GAG CTA TGT GCA 303  
 Ala Ile Leu Phe Ser Pro Arg Lys His Ser Lys Pro Glu Leu Cys Ala  
                     65                                    70                                    75

AAC CCT GAG GAA GGC TGG GTG CAG AAC CTG ATG CGC CGC CTG GAC CAG 351  
 Asn Pro Glu Glu Gly Trp Val Gln Asn Leu Met Arg Arg Leu Asp Gln  
                     80                                    85                                    90

CCT CCA GCC CCA GGG AAA CAA AGC CCC GGC TGC AGG AAG AAC CGG GGA 399  
 Pro Pro Ala Pro Gly Lys Gln Ser Pro Gly Cys Arg Lys Asn Arg Gly  
                     95                                    100                                    105

ACC TCT AAG TCT GGA AAG AAA GGA AAG GGC TCC AAG GGC TGC AAG AGA 447  
 Thr Ser Lys Ser Gly Lys Lys Gly Lys Gly Ser Lys Gly Cys Lys Arg  
                     110                                    115                                    120

ACT GAA CAG ACA CAG CCC TCA AGA GGA TAGCCAGTA GCCCGCCTGG 494  
 Thr Glu Gln Thr Gln Pro Ser Arg Gly  
                     125                                    130

AGCCCAGGAG ATCCCCCACG AACTTCAAGC TGGGTGGTTC ACGGTCCAAC TCACAGGCAA 554

AGAGGGAGCT AGAAAAACAGA CTCAGGAGCC GCTA 588

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 133 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ala Gln Met Met Thr Leu Ser Leu Leu Ser Leu Val Leu Ala Leu  
     1                    5                                    10                                    15

Cys Ile Pro Trp Thr Gln Gly Ser Asp Gly Gly Gly Gln Asp Cys Cys  
                     20                                    25                                    30

Leu Lys Tyr Ser Gln Lys Lys Ile Pro Tyr Ser Ile Val Arg Gly Tyr  
                     35                                    40                                    45

Arg Lys Gln Glu Pro Ser Leu Gly Cys Pro Ile Pro Ala Ile Leu Phe  
                     50                                    55                                    60

Ser Pro Arg Lys His Ser Lys Pro Glu Leu Cys Ala Asn Pro Glu Glu  
                     65                                    70                                    75                                    80

Gly Trp Val Gln Asn Leu Met Arg Arg Leu Asp Gln Pro Pro Ala Pro  
                     85                                    90                                    95

Gly Lys Gln Ser Pro Gly Cys Arg Lys Asn Arg Gly Thr Ser Lys Ser

|     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|
|     | 100 |     | 105 |     | 110 |
| Gly | Lys | Lys | Gly | Lys | Gly |
|     | 115 |     | 120 |     | 125 |
|     |     |     |     |     |     |
| Gln | Pro | Ser | Arg | Gly |     |
|     | 130 |     |     |     |     |

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 187 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "EST sequence"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| CAGACATGGC TCAGTCACTG GCTCTGAGCC TCCTTATCCT GGTCTNGCC TATGNAATCC  | 60  |
| CCAGGACCCA AGGCAGTGAT GGAGGGGCTC AGGACTGTTG CCTCAAGTAC AGCCAAAGGA | 120 |
| AGATTCCCGC CAAGGTTGTC CGCAGCTACC GGAAGCAGGA ACCAAGCTTA GGCTGCTCCA | 180 |
| TCCCAGC                                                           | 187 |

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 535 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "EST sequence"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| CAGTCACTGG CTCTGAGCCT CCTTATCCTG GTTCTGGCCT TTGNATCCCC AGGACCCAAG | 60  |
| GCAGTGATGG AGGGGCTCAG GACTGTTGCC TCAAGTACAG CCAAAGGAAG ATTCCCGCCA | 120 |
| AGGTTGTCCG CAGCTACCGG AAGCAGGAAC CAAGCTTAGG CTGCTCCATC CCAGCTATCC | 180 |
| TGTTCTTGCC CCGCAAGCGC TCTCAGGCAG AGCTATGTGC AGACCCAAAG GAGCTCTGGG | 240 |

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| TGCAGCAGCT GATGCAGCAT CTGGACAAGA CACCATCCCC ACAGAAACCA GCCCAGGGTG | 300 |
| CAGGAAGGAC AGGGGGGCCT CCAAGACTGG CAAGAAAGGA AAGGGCTCCA AAGGCTGCAA | 360 |
| GAGGACTGAG CGGTCACAGA CCCTAAAGGG CCATAGCCAG TGAGCAGCTG GAGCCTGGAG | 420 |
| ACCCACCAGC TNACAGCGTT GAANCTGAAC CAAGATNCAA GAAGGAGGTA TNTCAGGGGC | 480 |
| CTGGANAGCA CCCATGTGGC TTCANATCTT TGTCTGTTTA CACCCATTGA TTCAG      | 535 |

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CNTCCATCAC TGCCTTGGGT CCTGGGGAT

29

What is claimed is:

1. A composition comprising an isolated polynucleotide selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 80 to nucleotide 481;
  - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 149 to nucleotide 481;
  - (c) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1 encoding a protein having chemokine activity;
  - (d) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  - (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134;
  - (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having chemokine activity;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:1;
  - (h) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 85 to nucleotide 519;
  - (i) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 124 to nucleotide 519;
  - (j) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3 encoding a protein having chemokine activity;
  - (k) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
  - (l) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145;
  - (m) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having chemokine activity;
  - (n) a polynucleotide which is an allelic variant of SEQ ID NO:3;and

(o) a polynucleotide capable of hybridizing to any one of the polynucleotides specified in (a), (b), (d), (e), (h), (i), (k) or (l) above.

2. A composition of claim 1 wherein said polynucleotide is operably linked to an expression control sequence.

3. A host cell transformed with a composition of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein, which comprises:

(a) growing a culture of the host cell of claim 3 in a suitable culture medium; and

(b) purifying the protein from the culture

6. A protein produced according to the process of claim 5.

7. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134;

(c) fragments of the amino acid sequence of SEQ ID NO:2 having chemokine activity;

(d) the amino acid sequence of SEQ ID NO:4;

(e) the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145; and

(f) fragments of the amino acid sequence of SEQ ID NO:4 having chemokine activity;

the protein being substantially free from other mammalian proteins.

8. The composition of claim 7, further comprising a pharmaceutically acceptable carrier.
9. A composition comprising an antibody which specifically reacts with the protein of claim 7.
10. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 8.
11. The composition of claim 1 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 80 to nucleotide 481.
12. The composition of claim 1 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 149 to nucleotide 481.
13. The composition of claim 1 wherein said polynucleotide comprises a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2.
14. The composition of claim 1 wherein said polynucleotide comprises a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134.
15. The composition of claim 1 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 85 to nucleotide 519.
16. The composition of claim 1 wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 124 to nucleotide 519.

17. The composition of claim 1 wherein said polynucleotide comprises a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4.

18. The composition of claim 1 wherein said polynucleotide comprises a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145.

19. The composition of claim 7 wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

20. The composition of claim 7 wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 14 to amino acid 134.

21. The composition of claim 7 wherein said protein comprises the amino acid sequence of SEQ ID NO:4.

22. The composition of claim 7 wherein said protein comprises the amino acid sequence of SEQ ID NO:4 from amino acid 14 to amino acid 145.

23. An isolated gene corresponding to SEQ ID NO:1.

24. An isolated gene corresponding to SEQ ID NO:3.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/11908

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                   | Relevant to claim No. |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | WO 96/25497 A1 (INCYTE PHARMACEUTICALS, INC.) 22 August 1996 (22-08-96), pages 8-12                                                                                                                                                                  | 1-22                  |
| X         | WO 96/06169 A1 (HUMAN GENOME SCIENCES, INC.) 29 February 1996 (29-02-96), pages 1-3.                                                                                                                                                                 | 1-22                  |
| A         | JOSE et al. Eotaxin: Cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. Biochemical and Biophysical Research Communications. 30 November 1994, Vol. 205, No. 1, pages 788-794. | 1-24                  |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|                                                                                                                                                                         |                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * Special categories of cited documents:                                                                                                                                | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                                              |
| *A* document defining the general state of the art which is not considered to be of particular relevance                                                                | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                                                                     |
| *E* earlier document published on or after the international filing date                                                                                                | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | * & * document member of the same patent family                                                                                                                                                                                                  |
| *O* document referring to an oral disclosure, use, exhibition or other means                                                                                            |                                                                                                                                                                                                                                                  |
| *P* document published prior to the international filing date but later than the priority date claimed                                                                  |                                                                                                                                                                                                                                                  |

Date of the actual completion of the international search

19 AUGUST 1998

Date of mailing of the international search report

13 OCT 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:

*Caritha Lawrence for*  
PREMA MERTZ

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/11908

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/475, 14/52, 16/24; C12N 5/10, 15/12, 15/19, 15/63, 15/64; A61K 38/19, 48/00, 39/395

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/44, 2, 8, 12; 530/350, 387.1, 387.9; 424/85.1, 139.1, 145.1; 435/69.5, 71.1, 71.2, 471, 325, 252.3, 320.1, 471; 536/23.1, 23.5

## B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/44, 2, 8, 12; 530/350, 387.1, 387.9; 424/85.1, 139.1, 145.1; 435/69.5, 71.1, 71.2, 471, 325, 252.3, 320.1, 471; 536/23.1, 23.5

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, MEDLINE, CAPLUS, BIOSIS

search terms: LI05 protein, polypeptide, DNA, polynucleotide, cloning, recombinant production, antibody, treatment, therapy, administration